As of today, our company Origimm Biotechnology has been acquired by one of the largest pharmaceutical players, Sanofi.
This acquisition will provide Origimm with great opportunities to further expand its research capabilities, continue advancing science and developing highly innovative products for treating various skin diseases and infections associated with the many bacterial species that colonize our skin. The company will continue its operations in Vienna, our team remaining intact and excited about the new challenges ahead!
We are proud to announce the start of First-In-Human clinical trial of acne vulgaris vaccine, which is the major milestone for Origimm in bringing to clinical trial a world-wide first vaccine candidate against the bacteria involved in pathogenesis of acne.
The Phase I/IIa study will evaluate the safety and immunogenicity of the Origimm vaccine in acne patients, a possible breakthrough therapy for acne vulgaris. Relentless and dedicated efforts brought us to this point, and we are very grateful to our whole team for making this happen!